Y-mAbs CFO Bo Kruse to depart July 31; consultancy agreement for transition services through July 2025

Y-mAbs Therapeutics, Inc.

Kruse's last employment day is July 31, 2024; he receives a pro-rated 2024 bonus of $151,376 (DKK 1,035,867).
Pre-September 28, 2022 equity continues vesting per original terms; post-September 28, 2022 equity vests through July 31, 2025.
Consultancy via Investeringsselskabet GH ApS begins August 1, 2024 for one year, with a fixed monthly fee of $43,251 (DKK 295,967 excl. VAT).
Consulting covers financial operations and corporate governance; Kruse must assist with litigation arising from his tenure.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Bo Kruse

Executive Vice President, Chief Financial Officer, Treasurer and Secretary

Y-mAbs Therapeutics, Inc.

Effective: 2024-07-31
Filed: July 19, 2024, 7:59 PM ET

On July 16, 2024, in connection with the previously-disclosed resignation of Bo Kruse, the former Executive Vice President, Chief Financial Officer, Treasurer and Secretary of Y-mAbs Therapeutics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bo Kruse resigned as Executive Vice President, Chief Financial Officer, Treasurer and Secretary at Y-mAbs Therapeutics, Inc..

Action: resigned
Role: Executive Vice President, Chief Financial Officer, Treasurer and Secretary

Exact text from the filing

On July 16, 2024, in connection with the previously-disclosed resignation of Bo Kruse, the former Executive Vice President, Chief Financial Officer, Treasurer and Secretary of Y-mAbs Therapeutics, Inc.

View on SEC.gov

Source: SEC EDGAR

accession 0001558370-24-009915

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.